Haupt installs CPHU to cut CO2 emissions

By Nick Taylor

- Last updated on GMT

Related tags Carbon dioxide European union

CDMO Haupt Pharma has invested in a combined heat and power unit (CPHU) for its site in Wolfratshausen, Germany, which is now expected to produce 14 per cent less CO2 a year.

The contract development and manufacturing organisation (CDMO) has made the “forward-looking​” investment to realise environmental, financial and operational benefits.

CPHU, also known as cogeneration, captures and uses heat produced as a by-product in electricity generation. Conventional power plants emit heat, through cooling towers for example, and consequently are less energy efficient.

By installing CPHU Haupt believes it will cut the site’s CO2 emissions by 250,000 kg per year, which is approximately 14 per cent of total output. Given rising energy costs and the possibility of more stringent greenhouse gas emission reduction targets this cut could benefit Haupt in the long-term.

Haupt also anticipates making further energy savings in the future by integrating additional heat consumers to reduce waste, therefore improving the efficiency.

Furthermore, the CDMO said it will be able to act independently of an energy supplier, supplementing its own electricity with a reliable grid replacement in key areas such as sterile production, cold storage or media supplies.

Cogeneration forms part of the European Union’s energy policy and Germany has been particularly proactive in adopting more sustainable technologies. One aspect of this is the plan to double the number of cogeneration plants by 2020 to help cut electricity use by 11 per cent.

Sex hormone handling

Haupt has also built on the capabilities at its plant in Münster, Germany, adding a separate production area for sex hormones which are highly potent pharmacologically active substances.

To ensure the product, workforce and environment are protected from the hormones specific facilities and machinery are required. Haupt has met these requirements at its Münster plant by adding a facility which follows the closed and high-containment principle.

From this site Haupt will manufacture film- and sugar-coated tables. These will be packaged in blisters in a second production step.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers